A mouse model for encephalopathy induced by pertussis immunization has been described; it has features that closely resemble some of the severe reactions, including seizures and a shock-like state leading to death, occasionally seen after administration of Bordetella pertusssis (whooping cough) vaccine. Susceptibility to encephalopathy maps to genes of the major histocompatibility complex and correlates as well with the genetic regulation of the level of antibody response to bovine serum albumin. In this study we have investigated which bacterial determinant is responsible for the encephalopathy. Two lines of evidence implicate pertussis toxin as the active bacterial component. Single-site mutants of B. pertussis with single affected virulence factors were tested. A mutant that produces a defective pertussis toxin had greatly diminished capacity to induce encephalopathy, whereas a hemolysin-and adenylate-cyclase-deficient avirulent mutant had the same activity in the mouse model as a virulent strain. Purified pertussis toxin plus bovine serum albumin was tested and found to induce the lethal encephalopathy, demonstrating that the toxin was the critical constituent of B. pertussis responsible for encephalopathy.
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The pertussis vaccine component of diphtheria-pertussis-tetanus (DPT) vaccine is associated with convulsions in one of 1750 doses (1) , while severe and permanent neurologic damage has been calculated to occur with one of every 310,000 doses (2) . Although the benefits of the current pertussis vaccination program outweight the-risks by a considerable margin (3), development of a safer, efficacious vaccine is an important goal. In the past this effort has been hampered by lack of definitive information "about which bacterial antigens were essential for vaccine efficacy and which bacterial products were responsible for the reactogenicity.
A lethal-shock-like syndrome preceded by mnyoclonic seizures is induced in mice with an appropriate major histocompatibility (H-2) gene after immunization with heat-killed Bordetella pertussis vaccine and bovine serum albumin (BSA) (4, 5) . This model, which resembles post-pertussis immunization encephalopathy, involves daily injections alternating BSA with vaccine for 4 days, then a BSA challenge 5 days later. Death usually results within minutes of the final challenge. Previous studies have shown that the linkage of susceptibility to pertussis vaccine encephalopathy i i associated with high antibody responsiveness to BSA. The strain distribution of high immune responsiveness to BSA was identical to that reported by Riley et al. (6) and conforms to our results with susceptibility to B. pertussis encephalopathy. Thus, H-2d mice were high responders to BSA and highly susceptible to encephalopathy (57/65 died), while H-2b mice
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were low responders to BSA and totally resistant to B. pertussis encephalopathy induced with whole cell pertussis vaccine (0/44 died) (4, 5) TnS Insertion Mutants. TnS insertion mutants were derived from virulent strain BP338 (7) . The organisms were grown on Bordet-Gengou medium as previously described (7) for 2 days at 37°C. The cells were harvested, washed, and suspended to an optical density of 2.0 at 580 nM in phosphatebuffered saline, pH 6.5. This corresponds to 5-10 X 109 colony-forming units/ml. To produce a heat-killed vaccine, the bacteria were heated to 56°C for 30 min and 0.02% thimerosal was added. Vaccines were stored refrigerated for up to a week or frozen.
Pertussis Toxin. Pertussis toxin was concentrated on hydroxylapatite and then purified by chromatography on a fetuin affinity system (5, 8) .
Immunizations. For induction of encephalopathy mice were given killed B. pertussis organisms suspended in 0.2 ml of phosphate-buffered saline on days 0 and 2 by injection into the tail vein. On days -1, + 1, and +6 each mouse received 1 mg of BSA in 0.2 ml of phosphate-buffered saline intraperitoneally (i.p.). Mice were observed for the next 2 hr for seizures, shock, and death. For induction of BSA sensitivity, mice were immunized ip with 100 ,g of BSA in 0. (7) . Strain BP348 is ahemolysin adenylate cyclase-mutant but produces normal amounts of pertussis toxin (7) . The location of the TN5 insertion mutations has been determined by using a 32P-labeled DNA probe specific for TnS to hybridize to chromosomal DNA restriction fragments separated by electrophoresis (7). On these Southern hybridizations the EcoRI restriction fragment containing the site of the TnS insertion is distinct in the pertussis toxin mutant BP357 and differs from the insertion site in BP348 (7). and 1 x 108 heat-killed organisms, while for BP348 50% were killed at a dose between 108 and 2 x 108 organisms. BP357, the toxin-deficient strain, killed 50%o of the mice at a dose 5 x 109 organisms. The pertussis toxin mutant was significantly less potent than wild type (0/10 vs. 8/9 dead, P < 0.001 at 5
x 101 organisms, 0/11 vs. 7/11 dead, P < 0.002 at 108 organisms).
Since BP357 produced far less encephalopathogenicity than BP338, we asked whether pertussis toxin could substitute for BP338 in inducing encephalopathy, using the standard protocol. IgM) to BSA (9, 10). Even breast-fed babies have these serum antibodies, which are probably secondary to sensitization to BSA in the mother's milk (10, 11) .
We have shown that a particular component of B. pertussis, pertussis toxin, when combined with BSA sensitization can induce encephalopathy. This regimen with purified toxin not only is lethal in those strains susceptible to encephalopathy induced with whole cell vaccine but also can kill mice in H-2b strains that are remarkably resistant to encephalopathy induced with whole cell vaccines (0/44 H-2b mice killed with whole cell vaccine). It is rather remarkable that pertussis toxin plus BSA can be lethal in certain strains in which whole cell vaccines have no effect. It is also striking that the toxin is not lethal unless BSA is administered in the regimen. B. pertussis mutants induced with transposon TnS that have a defective pertussis toxin have much less encephalopathic potential than other wild-type B. pertussis organisms. Thus, we hypothesize that pertussis toxin contained in B. pertussis vaccine plus antibody to BSA triggers the encephalopathy. Part of the genetic susceptibility to encephalopathy resides in the capacity of the vaccine recipient to mount an anti-BSA response, while another component of susceptibility resides in the amount of pertussis toxin in the vaccine. 0/5 Mice (BALB/c) were given graded doses of 1 ml of pertussis toxin or B. pertussis intravenously on days 0 and 2. On days -1, +1, and +6 some mice were given 1 mg of BSA i.p. The number of dead mice was recorded within 2 hr of the day +6 injection. ND, not done. *At a pertussis toxin dose of 100 ng/ml on days 0 and 2, with administration of 1 mg of BSA on days -1, + 1, +6, 10/15 B10 mice and 4/10 BALB/b mice were dead within 2 hr of day +6 injection.
The mechanism whereby pertussis toxin and anti-BSA antibody combine to produce the damage is still uncertain. Why pertussis toxin plus BSA is encephalopathic even in H-2b mice is also unknown at present. Since H-2b mice make low-level anti-BSA antibody responses, we hypothesize that even they became encephalopathic with sufficient amounts of active pertussis toxin.
Pertussis toxin (8) , also referred to as pertussinogen, lymphocytosis-promoting factor, islet cell-activating protein, and histamine-sensitizing factor, is an oligomeric protein toxin with a wide range of physiologic effects, including increased sensitivity to anaphylaxis (12) , hyperinsulinemia (13) , and increased vascular permeability (14) . In addition to encephalopathic signs such as seizures and coma, systemic manifestations prior to death include cyanosis and tachypnea. Postmortem examination of susceptible mice after immunization with B. pertussis and BSA reveals widespread vascular congestion and some parenchymal hemorrhage in brain (4) . Whether the neurologic signs result from systemic changes such as shock, hypoglycemia, and ischemia (4) is unresolved at present. The molecular basis for the encephalopathic activity of pertussis toxin is not yet known.
By ADP-ribosylating the nucleotide-binding protein Ni, pertussis toxin prevents coupling of inhibitory synaptic receptors to adenylate cyclase (15) . Pertussis toxin can convert adenosine-induced inhibition of the release of synaptic glutamate in central nervous system nerve terminals to a stimulation of glutamate release (16) . Thus, pertussis toxin might induce encephalopathy through modulation of synaptic activity.
The identities of the antigens that are required to confer immunity to B. pertussis infection, as well as the roles that specific antigens play in bacterial virulence, can be established only by further examination. Antibody to pertussis toxin was effective for protection against B. pertussis infection in mice after either intracerebral or aerosol challenge with live B. pertussis (17) . Moreover, monoclonal antibody to a subunit of pertussis toxin protected mice against either intracerebral or aerosol challenge with B. pertussis (18) . In contrast, antibody to filamentous hemagglutinin did not protect against intracerebral challenge with B. pertussis. Thus, antibody to certain pertussis toxin epitopes may be sufficient to provide immunity to infection. It is not known at present whether antibody to mutant BP357, which lacks one of the pertussis toxin subunits, can provide effective immu-8736 Medical Sciences: Steinman et al. nity to B. pertussis infection. It is known, however, that the BP357 mutant was severely impaired in its capacity to induce lethal pertussis infection in mice (19) . Thus, pertussis toxin has a key role as a virulence factor in B. pertussis infection, and antibody to one of its subunits is sufficient to confer immunity. Precise information on the components of the pertussis toxin molecule responsible for antigenicity and protection, for bacterial virulence, and for encephalogenicity will be available with the cloning and sequencing of the pertussis toxin gene.
If the B. pertussis mutants deficient in pertussis toxin can immunize against natural B. pertussis infection, then this could lead to a B. pertussis vaccine safer than the one currently in use. Moreover, the model for B. pertussis immunization encephalopathy may serve to screen for the development of safer, genetically engineered B. pertussis vaccines. Vaccines containing sufficient pertussis toxin might have encephalopathic potential for genetically susceptible vaccine recipients.
